Jnana Therapeutics

SLC transporter Drug Discovery

5+ additional undisclosed programs RD immune-mediated & inflammatory diseases, oncology, neurology

Jnana Therapeutics is creating therapies to treat a wide variety of diseases by uncovering and targeting unique binding sites of highly validated protein targets. Chemoproteomics is facilitating drug discovery for previously inaccessible protein targets. Jnana has built a next-generation chemoproteomics platform, RAPID, to develop small molecule medicines for any target with unprecedented speed and efficiency. This approach is enabling Jnana to address a range of challenging target classes including SLC transporters, transcription factors and signaling scaffold proteins that are significant drivers of disease. Their lead candidate, JNT-517, is targeting a SLC transporter that plays a role in PKU.